针对丙型肝炎病毒1型感染的肾移植受者使用来迪派韦/索磷布韦治疗八周
Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection.
作者信息
Husson Jennifer S, Ravichandran Bharath, Jonchhe Srijana, Kottilil Shyamasundaran, Wilson Eleanor
机构信息
The Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD.
Department of Pharmacy, University of Maryland, Baltimore, MD.
出版信息
Transplant Direct. 2017 Nov 3;3(12):e229. doi: 10.1097/TXD.0000000000000744. eCollection 2017 Dec.
Short treatment duration of ledipasvir/sofosbuvir (LDV/SOF) has been successfully used to treat hepatitis C virus (HCV) genotype 1 infection in treatment-naive noncirrhotic patients with viral loads (VLs) under 6 million IU/mL. However, this short duration has not been studied in renal transplant recipients (RTRs), a patient population on lifelong immunosuppression. Here, we describe 3 RTRs who received 8 weeks of LDV/SOF, meeting the standard criteria for shortened treatment duration. All 3 patients tolerated treatment well and achieved sustained virologic response at 12 weeks (SVR 12).
对于初治的、病毒载量（VL）低于600万IU/mL的非肝硬化丙型肝炎病毒（HCV）1型感染患者，使用来迪派韦/索磷布韦（LDV/SOF）进行短疗程治疗已成功用于治疗。然而，这种短疗程在肾移植受者（RTR）中尚未得到研究，这是一类需要终身免疫抑制的患者群体。在此，我们描述了3例接受8周LDV/SOF治疗的RTR，他们符合缩短疗程的标准。所有3例患者对治疗耐受性良好，并在12周时实现了持续病毒学应答（SVR 12）。
Zotero 插件